PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 247 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q1 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,081,427 | -17.3% | 2,285,201 | +31.7% | 0.00% | 0.0% |
| Q2 2023 | $23,083,441 | -3.0% | 1,735,597 | -15.5% | 0.00% | -33.3% |
| Q1 2023 | $23,791,435 | +127.1% | 2,054,528 | +60.4% | 0.00% | +200.0% |
| Q4 2022 | $10,476,061 | -29.9% | 1,280,692 | -50.3% | 0.00% | -50.0% |
| Q3 2022 | $14,948,000 | +5.1% | 2,574,880 | -19.9% | 0.00% | 0.0% |
| Q2 2022 | $14,217,000 | -19.8% | 3,216,566 | +65.1% | 0.00% | 0.0% |
| Q1 2022 | $17,733,000 | -21.8% | 1,948,642 | +75.9% | 0.00% | -33.3% |
| Q4 2021 | $22,662,000 | -42.6% | 1,107,675 | -28.4% | 0.00% | -40.0% |
| Q3 2021 | $39,514,000 | +20.0% | 1,546,557 | +64.2% | 0.01% | +25.0% |
| Q2 2021 | $32,935,000 | +15.4% | 941,831 | +10.0% | 0.00% | 0.0% |
| Q1 2021 | $28,531,000 | +113.1% | 856,553 | +65.9% | 0.00% | +100.0% |
| Q4 2020 | $13,390,000 | +552.2% | 516,182 | +148.1% | 0.00% | – |
| Q3 2020 | $2,053,000 | -53.6% | 208,079 | -83.8% | 0.00% | -100.0% |
| Q2 2020 | $4,422,000 | +1060.6% | 1,281,654 | +929.8% | 0.00% | – |
| Q1 2020 | $381,000 | -95.3% | 124,457 | -92.1% | 0.00% | -100.0% |
| Q4 2019 | $8,093,000 | +76.3% | 1,574,518 | +77.0% | 0.00% | +100.0% |
| Q3 2019 | $4,590,000 | +71.8% | 889,601 | +101.5% | 0.00% | 0.0% |
| Q2 2019 | $2,671,000 | +63.9% | 441,450 | +95.8% | 0.00% | – |
| Q1 2019 | $1,630,000 | -28.0% | 225,474 | -26.3% | 0.00% | -100.0% |
| Q4 2018 | $2,264,000 | +79.8% | 305,938 | +31.5% | 0.00% | – |
| Q3 2018 | $1,259,000 | +18.5% | 232,655 | -22.2% | 0.00% | – |
| Q2 2018 | $1,062,000 | +85.3% | 299,075 | +7.1% | 0.00% | – |
| Q1 2018 | $573,000 | -12.8% | 279,121 | +12.2% | 0.00% | – |
| Q4 2017 | $657,000 | -27.3% | 248,852 | +44.5% | 0.00% | – |
| Q3 2017 | $904,000 | +149.0% | 172,258 | +68.9% | 0.00% | – |
| Q2 2017 | $363,000 | -95.5% | 101,973 | -93.4% | 0.00% | -100.0% |
| Q1 2017 | $7,996,000 | +211.4% | 1,547,038 | +129.0% | 0.00% | – |
| Q4 2016 | $2,568,000 | +406.5% | 675,490 | +1095.1% | 0.00% | – |
| Q3 2016 | $507,000 | -38.8% | 56,521 | -52.1% | 0.00% | – |
| Q2 2016 | $828,000 | +4.7% | 117,884 | +26.8% | 0.00% | – |
| Q1 2016 | $791,000 | -84.0% | 92,986 | -75.3% | 0.00% | -100.0% |
| Q4 2015 | $4,952,000 | +6974.3% | 377,149 | +1877.0% | 0.00% | – |
| Q3 2015 | $70,000 | -13.6% | 19,077 | +35.1% | 0.00% | – |
| Q2 2015 | $81,000 | +8.0% | 14,122 | +9.8% | 0.00% | – |
| Q1 2015 | $75,000 | -83.0% | 12,858 | -77.1% | 0.00% | – |
| Q4 2014 | $440,000 | +257.7% | 56,075 | +124.2% | 0.00% | – |
| Q3 2014 | $123,000 | -16.9% | 25,013 | +4.6% | 0.00% | – |
| Q2 2014 | $148,000 | -92.2% | 23,922 | -93.2% | 0.00% | -100.0% |
| Q1 2014 | $1,891,000 | +24.7% | 353,450 | +22.0% | 0.00% | 0.0% |
| Q4 2013 | $1,516,000 | +252.6% | 289,828 | +272.1% | 0.00% | – |
| Q3 2013 | $430,000 | +923.8% | 77,892 | +374.5% | 0.00% | – |
| Q2 2013 | $42,000 | – | 16,414 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |